tbuckley/cabot-search huggingface dataset:
Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis
Authors: Vanda Téglási, Lilla Reiniger, Katalin Fábián, Orsolya Pipek, Irén Csala, Attila G Bagó, Péter Várallyai, Laura Vízkeleti, Lívia Rojkó, József Tímár, Balázs Döme, Zoltán Szállási, Charles Swanton, Judit Moldvay
Journal: Neuro-Oncology (2017)

Management of lung cancer patients who suffer from brain metastases represents a major challenge. Considering the promising results with immune checkpoint inhibitor treatment, evaluating the status of immune cell (IC) infiltrates in the prognosis of brain metastasis may lead to better therapeutic strategies with these agents. The aim of this study was to characterize the distribution of ICs and determine the expression of the checkpoint molecules programmed death protein 1 (PD-1) and its ligand, PD-L1, in brain metastasis of lung adenocarcinoma (LUAD) patients and to analyze their clinicopathological correlations. We determined the presence of peritumoral mononuclear cells (mononuclear ring) and the density of intratumoral stromal mononuclear cells on brain metastasis tissue sections of 208 LUAD patients. PD-L1/PD-1 expressions were analyzed by immunohistochemistry. Mononuclear rings were significantly associated with better survival after brain metastasis surgery. Cases with massive stromal IC infiltration also showed a tendency for better overall survival. Lower expression of PD-1 and PD-L1 was associated with better survival in patients who underwent surgery for the primary tumor and had multiple brain metastases. Steroid administration and chemotherapy appear not to influence the density of IC in brain metastasis. This is the first study demonstrating the independent prognostic value of mononuclear rings in LUAD cases with brain metastasis. Our results also suggest that the density of tumor-associated ICs in addition to PD-L1 expression of tumor cells and ICs as well as PD-1 expression of ICs may hold relevant information for the appropriate selection of patients who might benefit from anti–PD-L1 or anti–PD-1 therapy.
Smoking and Postoperative Surgical Site Infection
Authors: John C. Alverdy, Vivek Prachand
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Acute Myeloid Leukemia-Derived Dendritic Cells Express the Immunoregulatory Enzyme Indoleamine 2,3-dioxygenase.
Authors: Antonio Curti, Simona Pandolfi, Michela Aluigi, Elisa Ferri, Emanuela Ottaviani, Ilaria Durelli, Alberto L. Horenstein, Francesca Fiore, Massimo Massaia, Milena Piccioli, Stefano A. Pileri, Giovanni Martinelli, Michele Baccarani, Roberto M. Lemoli
Journal: Blood (2006)
Abstract 15022: Alkaline Phosphatase Activity After Infant Cardiac Surgery: Kinetics and Association With Post-operative Cardiovascular Support
Authors: Jesse Davidson, Tracy T Urban, Suhong Tong, Mark Twite, Christine Baird, Ludmila Khailova, James Jaggers, Paul Wischmeyer
Journal: Circulation (2015)

Introduction: Alkaline phosphatase (AP) may be protective after CV surgery through dephosphorylation of endotoxin and extracellular adenine nucleotides. AP activity falls after infant CV surgery and low activity is associated with increased support requirements. However, the kinetics of AP loss and recovery, the isoenzymes involved, and the temporal relation of low AP activity to increased support are unknown. We hypothesized loss of all isoenzymes during surgery leads to decreased AP activity and that early low AP activity is associated with increased cardiovascular support at 6-48hr. Methods: Prospective study of 93 infants &lt;120 d/o undergoing CV surgery with bypass. Total/isoenzyme specific AP activity and vasoactive inotropic score (VIS) were obtained pre-operation, pre-separation and at 6, 24, 48 and 72hr after ICU admission. AP activities were determined by commercial assay and concentration by multiplex immunoassay. Low AP activity was defined as ≤80 U/L. Results: Median AP activity decreased through 6hr due to decreased bone and liver 2 isoenzyme activities (fig 1). Liver 1 isoenzyme increased post-bypass then decreased through 72hr. Activity was highly correlated with concentration at all time points (r=0.83-0.89; p&lt;0.0001). Nadir AP activity coincided with peak VIS. Infants with low AP activity at 6hr had significantly higher VIS through 48hr (6hr 12.1 vs 8.1, p&lt;0.0005; 24hr 11.2 vs 5.3, p&lt;0.0001; 48hr 6.9 vs 3.0, p&lt;0.0005). Similar findings occurred with low pre-separation and 24hr AP activity. On multivariate analysis, low AP activity at 6hr was independently associated with higher VIS at 6, 24 and 48hr. Conclusions: Loss of bone and liver 2 isoenzymes leads to decreased AP activity after infant CV surgery. Low early AP activity is associated with increased cardiovascular support requirements 6-48hr later. AP activity may serve as an early biomarker of post-operative hemodynamic instability and a potential therapeutic target in this population.
Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial
Authors: Joanna M Zakrzewska, Joanne Palmer, Valerie Morisset, Gerard MP Giblin, Mark Obermann, Dominik A Ettlin, Giorgio Cruccu, Lars Bendtsen, Mark Estacion, Dominique Derjean, Stephen G Waxman, Gary Layton, Kevin Gunn, Simon Tate
Journal: The Lancet Neurology (2017)
Appropriate Dose Adjustment of Dexamethasone Does Not Compromise Outcomes in Relapsed Refractory Multiple Myeloma
Authors: Abhisek Swaika, Vivek Roy, Zhuo Li, Neha Sood, Kristina Laumann, Amanda Shreders, Joseph Mikhael, Shaji Kumar, Asher Alban Chanan-Khan, Martha Q. Lacy, Sikander Ailawadhi
Journal: Blood (2015)
Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience
Authors: A.-K. Lalani, H. Li, D. Heng, L. Wood, A. Kalirai, G. Bjarnason, H.-W. Sim, C.K. Kollmannsberger, A. Kapoor, S.J. Hotte, M. Vanhuyse, P. Czaykowski, M.N. Reaume, D. Soulieres, P. Venner, S. North, N. Basappa
Journal: Annals of Oncology (2016)
Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) in solid tumors: results from the pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) cohorts
Authors: B. George, K. Kelly, A. Ko, H. Soliman, N. Trunova, Z. Wainberg, D. Waterhouse, P. O'Dwyer, H. Hochster
Journal: Annals of Oncology (2016)
Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&amp;7
Authors: Sita D. Bhella, Eshetu G Atenafu, Andre C Schuh, Mark D. Minden, Aaron D. Schimmer, Vikas Gupta, Matthew D. Seftel, Mohamed Shanavas, Andrzej Lutynski, Amr Rostom, Anna Rydlewski, Dina Khalaf, Karen W.L. Yee
Journal: Blood (2015)
Lentiviral Engineered T Regulatory Cells Effectively Inhibit Lymphocytes Alloreactivity across Major HLA Barriers
Authors: Dario Sangiolo, Noela Jordaney, Giulia Mesiano, Paola Circosta, Angela Elia, Stefania Stella, Maja Todorovic, Fabrizio Carnevale-Schianca, Massimo Aglietta, Alessandro Cignetti
Journal: Blood (2008)
A retrospective analysis of efficacy and safety of irinotecan plus cisplatin in ED-SCLC patients with pleural effusion
Authors: Yoshiyuki Sano, Tomoko Morita, Keisuke Kirita, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Hironobu Ohmatsu, Koichi Goto, Shinichiro Saitoh
Journal: Annals of Oncology (2016)
Non-Infectious Pulmonary Complication after Stem Cell Transplantation and Genetic Background
Authors: Makoto Onizuka, Nanae Kunii, Masako Toyosaki, Yoshihiro Inamoto, Kyoko Sugimoto, Koichi Miyamura, Yoshihisa Kodera, Kiyoshi Ando, Hidetoshi Inoko
Journal: Blood (2008)
Uncertain Future for Preexisting Conditions
Authors: Jeff Lyon
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Some Nutritional Factors Influencing the Origin and Development of Cancer
Authors: Harold P. Morris
Journal: JNCI Journal of the National Cancer Institute (1945)

Journal Article Some Nutritional Factors Influencing the Origin and Development of Cancer Get access Harold P. Morris Harold P. Morris Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 6, Issue 1, August 1945, Pages 1–17, https://doi.org/10.1093/jnci/6.1.1 Published: 01 August 1945
Pathogenesis of Diffuse Alveolar Hemorrhage in Murine Lupus
Authors: Haoyang Zhuang, Shuhong Han, Pui Y. Lee, Ravil Khaybullin, Stepan Shumyak, Li Lu, Amina Chatha, Anan Afaneh, Yuan Zhang, Chao Xie, Dina Nacionales, Lyle Moldawer, Xin Qi, Li‐Jun Yang, Westley H. Reeves
Journal: Arthritis & Rheumatology (2017)

Diffuse alveolar hemorrhage (DAH) in lupus patients confers >50% mortality, and the cause is unknown. We undertook this study to examine the pathogenesis of DAH in C57BL/6 mice with pristane-induced lupus, a model of human lupus-associated DAH.Clinical/pathologic and immunologic manifestations of DAH in pristane-induced lupus were compared with those of DAH in humans. Tissue distribution of pristane was examined by mass spectrometry. Cell types responsible for disease were determined by in vivo depletion using clodronate liposomes and antineutrophil monoclonal antibodies (anti-Ly-6G). The effect of complement depletion with cobra venom factor (CVF) was examined.After intraperitoneal injection, pristane migrated to the lung, causing cell death, small vessel vasculitis, and alveolar hemorrhage similar to that seen in DAH in humans. B cell-deficient mice were resistant to induction of DAH, but susceptibility was restored by infusing IgM. C3-/- and CD18-/- mice were also resistant, and DAH was prevented in wild-type mice by CVF. Induction of DAH was independent of Toll-like receptors, inflammasomes, and inducible nitric oxide. Mortality was increased in interleukin-10 (IL-10)-deficient mice, and pristane treatment decreased IL-10 receptor expression in monocytes and STAT-3 phosphorylation in lung macrophages. In vivo neutrophil depletion was not protective, while treatment with clodronate liposomes prevented DAH, which suggests that macrophage activation is central to DAH pathogenesis.The pathogenesis of DAH involves opsonization of dead cells by natural IgM and complement followed by complement receptor-mediated lung inflammation. The disease is macrophage dependent, and IL-10 is protective. Complement inhibition and/or macrophage-targeted therapies may reduce mortality in lupus-associated DAH.
Surrogate endpoints for overall survival in loco-regionally advanced nasopharyngeal carcinoma: Results from the individual patient data meta-analysis MAC-NPC2
Authors: F. Rotolo, J.-P. Pignon, S. Marguet, J. Ma, A.T.C. Chan, P.-Y. Huang, G. Zhu, D.T. Chua, Y. Chen, H.-Q. Mai, D.W. Kwong, Y.L. Soong, J. Moon, Y. Tung, K.-H. Chi, G. Fountzilas, L. Zhang, A. Lee, P. Blanchard, S. Michiels
Journal: Annals of Oncology (2016)
Increasing Wnt3a Signaling in Myeloma Cells Inhibits the Osteolytic Phenotype and Tumor Growth In Vivo through Regulation of the RANKL/OPG Axis in Osteoblasts and Indirectly Regulates Osteoclastogenesis.
Authors: Ya-Wei Qiang, Nathan Brown, Yu Chen, Shmuel Yaccoby, Bart Barlogie, John D. Shaughnessy
Journal: Blood (2007)
SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting
Authors: E. Dean, N. Steele, H.-T. Arkenau, F. Blackhall, N.M. Haris, C. Lindsay, S. Rafii, R. Califano, R. Plummer, M. Voskoboynik, Y.J. Summers, D. Ghiorghiu, A. Dymond, K. So, A. Greystoke
Journal: Annals of Oncology (2016)
Axl Receptor Tyrosine Kinase Signaling Pathway and the p53 Tumor Suppressor Protein Exist In A Novel Regulatory Loop In B-Cell Chronic Lymphocytic Leukemia Cells
Authors: Asish K Ghosh, Justin Boysen, Tammy Price-troska, Charla Secreto, Clive S. Zent, Neil Kay
Journal: Blood (2011)
‘ <i>VisionZero</i> ’: Is it achievable for rugby-related catastrophic injuries in South Africa?
Authors: James Brown, Wayne Viljoen, Clint Readhead, Gail Baerecke, Mike Lambert, Caroline F Finch
Journal: British Journal of Sports Medicine (2017)

South Africa is home to an estimated 53 million people, 400 000 of whom play rugby union (‘rugby’) (www.worldrugby.com). Although rare, rugby can be associated with permanently disabling injuries, which are tragic for the player and their family and also negative for the sport’s image.1 To reduce these injuries, a nationwide injury prevention programme, called ‘BokSmart’ (www.boksmart.com), was launched in South Africa in 2009.

Due to its vast socioeconomic disparities, South Africa is a difficult context for the implementation of any health intervention, let alone injury prevention programmes. South Africa ranks as the most inequitable country in the world (www.data.worldbank.org). Moreover, this inequity extends to healthcare: a recent report indicated that the poorest quintile of South Africans receive <10% of the country’s health benefits despite requiring close to 40% of these services, according to their self-reported health (figure 1).2 This disparity is partly due to infrastructure deficiencies in under-resourced communities. For example, rugby coaches in low socioeconomic areas mentioned infrastructure-related barriers to implementing BokSmart that were not mentioned by coaches from high socioeconomic areas.3 The fact that the same programme/strategy is implemented into different …
An optimal cumulative dose of cisplatin in chemoradiotherapy as a definitive treatment for non-metastatic nasopharyngeal carcinoma: a retrospective multicenter study
Authors: P. Danchaivijitr, N. Ngamphaiboon, C. Jiarpinitnun, E. Sirachainan, P. Pattaranutaporn, J. Setakornnukul
Journal: Annals of Oncology (2016)
Pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM): randomized, phase 3 KEYNOTE-185 study
Authors: A. Palumbo, M.-V. Mateos, J. San Miguel, J. Shah, S. Thompson, P. Marinello, S. Jagannath
Journal: Annals of Oncology (2016)
Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Benefit from the Newer Drugs Used in the Relapsed Setting.
Authors: Roman Hajek, Marta Krejci, Vlastimil Scudla, Elena Tothova, Martin Mistrik, Jaroslav Bacovsky, Miroslava Schutzova, Vladimir Koza, Tomas Papajik, Libuse Novosadova, Hana Frankova, Yvetta Stavarova, Frantisek Lehanka, Milena Vranova, Petr Kessler, Marketa Zemanova, Ivana Meluzinova, Nadezda Seifertova, Elen Sumna, Ludek Pour, Vladimir Maisnar, Zdenek Adam
Journal: Blood (2008)
Activation of stroma-derived matrix metalloproteinases (MMPs) in a model of gastric cancer
Authors: Sandhir Kandola, Christopher Holmberg, Bart Ghesquière, Francis Impens, Kris Gevaert, J. Dinesh Kumar, Nicole Cash, Peter Hegyi, Nikolina Vlatkovic, Timothy Wang, Graham Dockray, Andrea Varro
Journal: Cancer Research (2013)
Anaplastic Lymphoma Kinase Is Activated through the Pleiotrophin/Receptor Protein Tyrosine Phosphatase (RPTP)β/ζ Signaling Pathway: A Unique Mechanism of Activation of Receptor Protein Tyrosine Kinases.
Authors: Pablo Perez-Pinera, Wei Zhang, Zhaoyi Wang, James R. Berenson, Thomas F. Deuel
Journal: Blood (2006)
Allergic reactions (ARs) induced by FOLFOX4 treatment in colorectal cancer: A comparative analysis between Asian and Western patients (pts).
Authors: K. Sugihara, A. Ohtsu, Y. Shimada, N. Mizunuma, P. Lee, A. De Gramont, R. M. Goldberg, M. L. Rothenberg, T. Andre, S. Brienza
Journal: Journal of Clinical Oncology (2011)

3623 Background: FOLFOX4 is a standard regimen either in the palliative or adjuvant chemotherapy for colorectal cancer. We previously reported the safety results of 2 Asian and 4 Western studies of FOLFOX4 (ASCO 2010, No.3611). This report summarizes ARs in these studies. Methods: A total of 3,359 colorectal cancer pts, 1,515 Asian and 1,844 Western, treated with FOLFOX4 from 2 Asian [J-PMS (Jpn Post Marketing Surveillance) and MASCOT] and 4 Western [de Gramont 1st line phase III (EFC2962), Goldberg 1st line phase III (N9741), Rothenberg 2nd line phase III (EFC4584) and MOSAIC] studies were included in this report. ARs were defined as anaphylactic reaction, anaphylactic shock, anaphylactoid reaction, drug hypersensitivity or hypersensitivity, and graded by NCI-CTC. They were collected prospectively and re-coded by MedDRA ver 9.0. Results: Pts received FOLFOX4 for median 6-12 cycles over median 16-28 weeks. There were no marked differences in dose intensity of oxaliplatin between 2 Asian and 4 Western studies. Grade ≥1 ARs were observed in 3.2-25% of pts and grade ≥3 in 0.6-3.1%. The incidence of ARs tended to increase modestly from 5-7 cycles of treatment. Many of grade ≥3 ARs developed without the preceding episode of grade-1 or -2 ARs. The cumulative doses of oxaliplatin that induced grade ≥1 ARs in 10% pts (CD10) calculated by Kaplan-Meier method were 595-1,280 mg/m2 with moderate variations among the studies. Analysis of correlation between ARs and demographic/baseline characteristics by multivariate logistic regression showed no significant regional differences. Conclusions: Although there were slight differences in incidences and CD10 of grade ≥1 ARs, no marked differences were observed in incidences of grade ≥3 ARs between Asian and Western pts treated with FOLFOX4. J-PMS MASCOT EFC2962 N9741 EFC4584 MOSAIC Line 1st ≥2nd Adjuvant 1st 1st 2nd Adjuvant Pt No. 222 1,134 159 209 259 268 1,108 Median cycles 8 6 12* 12 10 7 12* L-OHP CD (mg/m2) 657 500 967 839 765 589 888 Grade ≥ 1 ARs (%) 8.1 3.2 25.2 7.2 12.4 6.3 10.3 Grade ≥ 3 ARs (%) 2.3 0.6 3.1 1.9 1.5 1.1 3.0 Grade 4 ARs (%) 0 0.2 0.6 0.5 0 0.4 0.6 L-OHP CD10 (mg/m2) 889** 595 1,122 683 1,280 759 * Max 12 cycles. ** n=1,356.
CSIG-09. ERK1/2-DRIVEN SPROUTY2 EXPRESSION MEDIATES RESISTANCE TO RECEPTOR TYROSINE KINASE-TARGETED THERAPEUTICS IN GLIOBLASTOMA CELLS
Authors: Evan Day, Matthew Lazzara
Journal: Neuro-Oncology (2016)

The therapeutic efficacy of inhibitors of oncogenic kinases in glioblastoma multiforme (GBM) has been disappointing to date. In glioblastoma and other malignancies, resistance to targeted therapeutics can arise through dynamic rewiring of cell signaling pathways responsible for tumorigenesis and survival. Here, we identify a signaling rewiring process in glioblastoma cells that promotes expression of Sprouty2 (SPRY2). We recently identified SPRY2 as a driver of glioblastoma cell and tumor proliferation and resistance to kinase inhibitors. Specifically, we found that SPRY2 depletion reduced the ability of glioblastoma cells to form colonies in soft agar, to form subcutaneous tumors in mice, and to resist co-inhibition of the EGFR and MET receptor tyrosine kinases. In the present study we found that, in a panel of glioblastoma cell lines, SPRY2 expression was initially reduced in response to inhibition of EGFR and MET. However, 24-48 hours after receptor inhibition, resurgent SPRY2 expression was observed while EGFR and MET phosphorylation remained suppressed. Multivariate measurements of several kinases downstream of EGFR and MET revealed that phosphorylated ERK1/2, which was initially suppressed in response to EGFR and MET inhibition, also displayed a resurgence that paralleled SPRY2 expression. This correlation between ERK phosphorylation and SPRY2 expression is consistent with the documented ability of ERK to regulate SPRY2 transcription. Antibody array analysis suggested that ERK reactivation is mediated by other RTKs activated in response to EGFR and MET inhibition. This analysis was supported further by measuring transcriptional differences in ligands responsible for activating these receptors. Suppression of the alternate RTKs’ activity through inhibitors and siRNA augmented response to EGFR and MET inhibitors. We hypothesize that resurgent ERK phosphorylation and resultant SPRY2 expression occur due to the ability of glioblastoma cells to activate alternative RTKs. Thus, targeting multiple RTKs could be a way to overcome resistance to single RTK inhibitor treatments.
Resveratrol Ameliorates TNFα-Mediated Suppression of Erythroid Colony Formation in Human CD34+ Cells Via Cellular Pathways Involving Downregulation of NF-κB.
Authors: Matthew Silver, Jee-Yeong Jeong, Aric Parnes, Masha Sverdlov, Nancy Berliner, K. Gary J. Vanasse
Journal: Blood (2009)